The Long-term Survival of a Patient With Pancreatic Cancer

This is a fascinating read about man with Pancreatic Cancer and his success on LDN. If you know someone with pancreatic cancer or someone who is on or considering Chemotherapy, TELL them about Low Dose Naltrexone. 


In this case report, we describe the treatment of a 46- year-old man who was diagnosed with metastatic pan- creatic cancer in October 2002. He was initially sur- veyed and staged by a local oncology team and treated with a standard chemotherapy regimen. After a single treatment of gemcitabine and carboplatin, the patient became leukopenic and thrombocytopenic and could not tolerate any further chemotherapy. In addition, even with the standard chemotherapy protocol, his cancer progressed.

J.A. then arrived at the office of one of the authors (B.M.B.) and was promptly started on a program of intravenous ALA, LDN, and a healthy lifestyle pro- gram. During the period from October 2002 to pres- ent (December 2005), J.A.’s pancreatic cancer with metastases to the liver was followed closely by regular office visits and CT and PET scans, and he has remained mostly stable (Figure 7). It is interesting to note that J.A.’s disease progressed rapidly when he

went off the ALA-LDN therapy; however, it stabilized quickly when he resumed the treatment.

J.A. went back to work soon after he started the ALA-LDN integrative treatment protocol and remains free of symptoms at 3 years and 3 months. The authors believe that since most people with metastatic pancre- atic cancer succumb to their disease miserably within a very short time, the 39-month survival time with non- progressive disease reported here represents a bench- mark in oncology. People with metastatic pancreatic cancer more often die from their disease or complica- tions thereof within 6 months and usually after a very stressful and painful course. The report above is thus of great importance.

In summary, the integrative therapy described in this article may have the possibility of extending the life of a patient who is customarily considered termi- nal. This was accomplished with a program of univer- sal antioxidants, one that bears known antitumor activity (ALA) and an opiate-blockading agent that can stimulate an endogenous immune response. The authors believe that biomedical science will one day develop a cure for metastatic pancreatic cancer, per- haps via gene therapy or another biological-type plat- form. But until such protocols come to market, and moreover evolve and become realized, the ALA/LDN therapy should be considered given its lack of toxicity at levels reported herein, ready availability, and its effect on J.A., the true subject of this report."- INTEGRATIVE CANCER THERAPIES 5(1); 2006 Burton M. Berkson, Daniel M. Rubin, and Arthur J. Berkson